Cite
Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists.
MLA
Sun, Lei, et al. “Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists.” Pharmaceuticals (14248247), vol. 15, no. 6, June 2022, p. 740–N.PAG. EBSCOhost, https://doi.org/10.3390/ph15060740.
APA
Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P. (2022). Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists. Pharmaceuticals (14248247), 15(6), 740–N.PAG. https://doi.org/10.3390/ph15060740
Chicago
Sun, Lei, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, and Peng Wang. 2022. “Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists.” Pharmaceuticals (14248247) 15 (6): 740–N.PAG. doi:10.3390/ph15060740.